NASDAQ:VTGN VistaGen Therapeutics (VTGN) Stock Price, News & Analysis $0.30 +0.02 (+8.79%) Closing price 04:00 PM EasternExtended Trading$0.29 -0.01 (-3.70%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About VistaGen Therapeutics Stock (NASDAQ:VTGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VistaGen Therapeutics alerts:Sign Up Key Stats Today's Range$0.27▼$0.3250-Day Range$0.23▼$0.3752-Week Range$0.20▼$5.14Volume5.95 million shsAverage Volume5.23 million shsMarket Capitalization$13.18 millionP/E RatioN/ADividend YieldN/APrice Target$0.95Consensus RatingReduce Company Overview Vistagen Therapeutics, Inc. (NASDAQ: VTGN), formerly known as VistaGen Therapeutics, is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. The company’s research centers on neuroactive nasal spray medicines designed to act rapidly and potentially avoid some of the systemic side effects associated with conventional treatments. Vistagen’s lead product candidate is fasedienol, also known as PH94B, an investigational nasal spray being developed for anxiety-related disorders, including social anxiety disorder. The company is also advancing PH10, an intranasal neuroactive drug candidate being studied for depressive disorders, and PH80, a nasal spray candidate investigated for conditions such as migraine. These products remain investigational and have not been approved for commercial use. Vistagen’s product candidates originated from research involving pherines, synthetic neuroactive compounds intended to influence neural pathways through the nasal cavity. The company is headquartered in South San Francisco, California, and its development activities are primarily focused on the U.S. market. Vistagen is led by President and Chief Executive Officer Shawn K. Singh.AI Generated. May Contain Errors. Read More VistaGen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreVTGN MarketRank™: VistaGen Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 754th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingVistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialVistaGen Therapeutics has a consensus price target of $0.95, representing about 232.2% upside from its current price of $0.29.Amount of Analyst CoverageVistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VistaGen Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VistaGen Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.28% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 7.64.Change versus previous monthShort interest in VistaGen Therapeutics has recently increased by 27.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.05 News SentimentVistaGen Therapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for VistaGen Therapeutics this week, compared to 5 articles on an average week.Search Interest6 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.93% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VistaGen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Stock News HeadlinesAgenus (NASDAQ:AGEN) and VistaGen Therapeutics (NASDAQ:VTGN) Head-To-Head ContrastSeptember 27 at 8:15 AM | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)September 24, 2026 | theglobeandmail.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 28 at 1:00 AM | Porter & Company (Ad)Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety DisorderSeptember 24, 2026 | globenewswire.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Rating of "Reduce" by AnalystsSeptember 23, 2026 | americanbankingnews.comVistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock UpSeptember 22, 2026 | rttnews.comVistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderSeptember 22, 2026 | globenewswire.comCritical Comparison: VistaGen Therapeutics (NASDAQ:VTGN) versus Zenas BioPharma (NASDAQ:ZBIO)September 22, 2026 | americanbankingnews.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? VistaGen Therapeutics' stock was trading at $0.6619 at the start of the year. Since then, VTGN stock has decreased by 56.8% and is now trading at $0.2860. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its earnings results on Friday, August, 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.07. The firm earned $1.48 million during the quarter, compared to analysts' expectations of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative trailing twelve-month return on equity of 152.59%. When did VistaGen Therapeutics' stock split? VistaGen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are VistaGen Therapeutics' major shareholders? Top institutional investors of VistaGen Therapeutics include ADAR1 Capital Management LLC (0.79%), BlackRock Inc. (0.78%), BlackRock Inc. (0.58%) and Man Group plc (0.25%). View institutional ownership trends. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2026Today9/28/2026Next Earnings (Estimated)11/12/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VTGN's financial health is in the Red zone, according to TradeSmith. VTGN has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees41Year Founded1998Price Target and Rating Average Price Target for VistaGen Therapeutics$0.95 High Price Target$1.00 Low Price Target$0.90 Potential Upside/Downside+219.9%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net Margins-2,702.64% Pretax Margin-2,702.36% Return on Equity-152.59% Return on Assets-117.45% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual Sales$1.27 million Price / Sales10.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.33Miscellaneous Outstanding Shares44,380,000Free Float43,077,000Market Cap$13.18 million OptionableOptionable Beta0.39 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:VTGN) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our Partners"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTGN Stock Alerts